SEC Form 4 · accession 0001193125-26-332547
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karah Herdman Parschauer
Officer — EVP and Chief Legal Officer
Period of report
Aug 3, 2026
Accepted (ET)
Aug 4, 2026 · 3:15 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 3, 2026 | S | 1,900 | $24.92 | D | 92,562 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.